Proteomics and kidney stone disease

Contributions to Nephrology

Volumn 160, Issue , 2008, Pages 142-158

  Thongboonkerd, V ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TFF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

AMINO ACID SEQUENCE; GENETICS; HUMAN; METHODOLOGY; MOLECULAR GENETICS; NEPHROLITHIASIS; PROTEOMICS; REVIEW; URINE;

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; HUMANS; KIDNEY CALCULI; MOLECULAR SEQUENCE DATA; PROTEOMICS; TUMOR SUPPRESSOR PROTEINS;

EID: 48949095632     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000125972     Document Type: Review

References (75)

1. Ramello A, Vitale C, Marangella M: Epidemiology of nephrolithiasis. J Nephrol 2000;13(suppl 3):S45-S50.
2. Coe FL, Parks JH, Asplin JR: The pathogenesis and treatment of kidney stones. N Engl J Med 1992;327:1141-1152.
3. Lieske JC, Deganello S: Nucleation, adhesion, and internalization of calcium-containing urinary crystals by renal cells. J Am Soc Nephrol 1999;10(suppl 14):S422-S429.
4. Parks JH, Coward M, Coe FL: Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 1997;51:894-900.
5. Mandel N: Mechanism of stone formation. Semin Nephrol 1996;16:364-374.
6. Kok DJ, Papapoulos SE, Bijvoet OL: Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 1990;37:51-56.
7. Lieske JC, Swift H, Martin T, Patterson B, Toback FG: Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. Proc Natl Acad Sci USA 1994;91:6987-6991.
8. Lieske JC, Deganello S, Toback FG: Cell-crystal interactions and kidney stone formation. Nephron 1999;81(suppl 1):8-17.
9. Finlayson B, Reid F: The expectation of free and fixed particles in urinary stone disease. Invest Urol 1978;15:442-448.
10. Kok DJ, Khan SR: Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 1994;46:847-854.
11. Tomazic BB, Nancollas GH: The dissolution of calcium oxalate kidney stones. A kinetic study. J Urol 1982;128:205-208.
12. Ryall RL: Glycosaminoglycans, proteins, and stone formation: adult themes and child's play. Pediatr Nephrol 1996;10:656-666.
13. Coe FL, Nakagawa Y, Asplin J, Parks JH: Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab 1994;20:378-384.
14. Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J: Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003;14:139-147.
15. Hess B: Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 1994;20:393-398.
16. Randall A: The origin and growth of renal calculi. Ann Surg 1937;105:1009-1027.
17. Low RK, Stoller ML: Endoscopic mapping of renal papillae for Randall's plaques in patients with urinary stone disease. J Urol 1997;158:2062-2064.
18. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M: Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003;111:607-616.
19. Bushinsky DA: Nephrolithiasis: site of the initial solid phase. J Clin Invest 2003;111:602-605.
20. Evan AP, Lingeman JE, Coe FL, Shao Y, Parks JH, Bledsoe SB, Phillips CL, Bonsib S, Worcester EM, Sommer AJ, Kim SC, Tinmouth WW, Grynpas M: Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 2005;67:576-591.
21. Pak CY, Poindexter JR, Peterson RD, Heller HJ: Biochemical and physicochemical presentations of patients with brushite stones. J Urol 2004;171:1046-1049.
22. Nakagawa Y, Ahmed M, Hall SL, Deganello S, Coe FL: Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in γ-carboxyglutamic acid. J Clin Invest 1987;79:1782-1787.
23. Pak CY: Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest 1969;48:1914-1922.
24. Thongboonkerd V, Klein JB (eds): Proteomics in Nephrology. Contrib Nephrol. Basel, Karger, 2004, vol 141, pp 1-327.
25. Thongboonkerd V: Proteomics in nephrology: current status and future directions. Am J Nephrol 2004;24:360-378.
26. Thongboonkerd V, Malasit P: Renal and urinary proteomics: current applications and challenges. Proteomics 2005;5:1033-1042.
27. Thongboonkerd V: Proteomic analysis of renal diseases: unraveling the pathophysiology and biomarker discovery. Expert Rev Proteomics 2005;2:349-366.
28. Thongboonkerd V: Recent progress in urinary proteomics. Proteomics Clin Appl 2007;1:780-791.
29. Thongboonkerd V: Practical points in urinary proteomics. J Proteome Res 2007;6:3881-3890.
30. Klein E, Klein JB, Thongboonkerd V: Two-dimensional gel electrophoresis: a fundamental tool for expression proteomics studies. Contrib Nephrol. Basel, Karger, 2004, vol 141, pp 25-39.
31. Lilley KS, Friedman DB: All about DIGE: quantification technology for differential-display 2Dgel proteomics. Expert Rev Proteomics 2004;1:401-409.
32. Marouga R, David S, Hawkins E: The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005;382:669-678.
33. McCormack AL, Schieltz DM, Goode B, Yang S, Barnes G, Drubin D, Yates JR III: Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal Chem 1997;69:767-776.
34. Wu CC, MacCoss MJ, Howell KE, Yates JR III: A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 2003;21:532-538.
35. Gygi SP, Rist B, Griffin TJ, Eng J, Aebersold R: Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J Proteome Res 2002;1:47-54.
36. Washburn MP, Wolters D, Yates JR III: Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19:242-247.
37. Goodchild A, Raftery M, Saunders NF, Guilhaus M, Cavicchioli R: Cold adaptation of the Antarctic archaeon, Methanococcoides burtonii, assessed by proteomics using ICAT. J Proteome Res 2005;4:473-480.
38. 12C-based, acid-cleavable isotope-coded affinity tag reagent and modified data acquisition scheme. Proteomics 2005;5:380-387.
39. Choe LH, Aggarwal K, Franck Z, Lee KH: A comparison of the consistency of proteome quantitation using two-dimensional electrophoresis and shotgun isobaric tagging in Escherichia coli cells. Electrophoresis 2005;26:2437-2449.
40. Chong PK, Gan CS, Pham TK, Wright PC: Isobaric tags for relative and absolute quantitation (iTRAQ) reproducibility: implication of multiple injections. J Proteome Res 2006;5:1232-1240.
41. Aggarwal K, Choe LH, Lee KH: Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 2006;5:112-120.
42. Wiese S, Reidegeld KA, Meyer HE, Warscheid B: Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 2007;7:340-350.
43. Fung E, Diamond D, Simonsesn AH, Weinberger SR: The use of SELDI ProteinChip array technology in renal disease research. Methods Mol Med 2003;86:295-312.
44. Petricoin EF, Liotta LA: Clinical proteomics: application at the bedside. Contrib Nephrol. Basel, Karger, 2004, vol 141, pp 93-103.
45. Jones WT, Resnick MI: The characterization of soluble matrix proteins in selected human renal calculi using two-dimensional polyacrylamide gel electrophoresis. J Urol 1990;144:1010-1014.
46. Binette JP, Binette MB: Sequencing of proteins extracted from stones. Scanning Microsc 1994;8:233-239.
47. Binette JP, Binette MB, Gawinowicz MA, Kendrick N: Urinary stone proteins: an update. Scanning Microsc 1996;10:509-517.
48. Kaneko K, Yamanobe T, Nakagomi K, Mawatari K, Onoda M, Fujimori S: Detection of prothrombin and osteopontin in a renal stone found in a hyperuricemic patient using 2D-PAGE and LC-MS analysis. Nucleosides Nucleotides Nucleic Acids 2004;23:1127-1129.
49. Kaneko K, Yamanobe T, Nakagomi K, Mawatari K, Onoda M, Fujimori S: Detection of protein Z in a renal calculus composed of calcium oxalate monohydrate with the use of liquid chromatography-mass spectrometry/mass spectrometry following two-dimensional polyacrylamide gel electrophoresis separation. Anal Biochem 2004;324:191-196.
50. Kaneko K, Yamanobe T, Onoda M, Mawatari K, Nakagomi K, Fujimori S: Analysis of urinary calculi obtained from a patient with idiopathic hypouricemia using micro area x-ray diffractometry and LC-MS. Urol Res 2005;33:415-421.
51. Mushtaq S, Siddiqui AA, Naqvi ZA, Rattani A, Talati J, Palmberg C, Shafqat J: Identification of myeloperoxidase, -defensin and calgranulin in calcium oxalate renal stones. Clin Chim Acta 2007;384:41-47.
52. Forterre S, Raila J, Kohn B, Brunnberg L, Schweigert FJ: Protein profiling of organic stone matrix and urine from dogs with urolithiasis. J Anim Physiol Anim Nutr (Berl) 2006;90:192-199.
53. Grover PK, Resnick MI: Evidence for the presence of abnormal proteins in the urine of recurrent stone formers. J Urol 1995;153:1716-1721.
54. Papale M, Pedicillo MC, Thatcher BJ, Di Paolo S, Lo ML, Bufo P, Rocchetti MT, Centra M, Ranieri E, Gesualdo L: Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856:205-213.
55. Poon TC: Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007;4:51-65.
56. Cadieux PA, Beiko DT, Watterson JD, Burton JP, Howard JC, Knudsen BE, Gan BS, McCormick JK, Chambers AF, Denstedt JD, Reid G: Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal 2004;18:170-175.
57. Koide T, Yoshioka T, Yamaguchi S, Hosokawa S, Utsunomiya M, Sonoda T: Urinary crystal surface binding substances on calcium oxalate crystals. Urol Res 1990;18:387-392.
58. Hess B: Tamm-Horsfall glycoprotein - inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 1992;20:83-86.
59. Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG: Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 1992;89:426-430.
60. Atmani F, Khan SR: Role of urinary bikunin in the inhibition of calcium oxalate crystallization. J Am Soc Nephrol 1999;10(suppl 14):S385-S388.
61. Ryall RL, Grover PK, Stapleton AM, Barrell DK, Tang Y, Moritz RL, Simpson RJ: The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci (Lond) 1995;89:533-541.
62. Han IS, Nakagawa Y, Park JW, Suh MH, Suh SI, Shin SW, Ahn SY, Choe BK: FKBP-12 exhibits an inhibitory activity on calcium oxalate crystal growth in vitro. J Korean Med Sci 2002;17:41-48.
63. Tsujihata M, Miyake O, Yoshimura K, Kakimoto KI, Takahara S, Okuyama A: Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. J Urol 2000;164:1718-1723.
64. Selvam R, Kalaiselvi P: A novel basic protein from human kidney which inhibits calcium oxalate crystal growth. BJU Int 2000;86:7-13.
65. Chutipongtanate S, Nakagawa Y, Sritippayawan S, Pittayamateekul J, Parichatikanond P, Westley BR, May FE, Malasit P, Thongboonkerd V: Identification of human urinary trefoil factor-1 as a novel calcium oxalate crystal growth inhibitor. J Clin Invest 2005;115:3613-3622.
66. Chadwick MP, Westley BR, May FE: Homodimerization and hetero-oligomerization of the single-domain trefoil protein pNR-2/pS2 through cysteine 58. Biochem J 1997;327:117-123.
67. Polshakov VI, Williams MA, Gargaro AR, Frenkiel TA, Westley BR, Chadwick MP, May FE, Feeney J: High-resolution solution structure of human pNR-2/pS2: a single trefoil motif protein. J Mol Biol 1997;267:418-432.
68. Thongboonkerd V, Chutipongtanate S, Semangoen T, Malasit P: Urinary trefoil factor-1 is a novel potent inhibitor of calcium oxalate crystal growth and aggregation and can transform calcium oxalate monohydrate to dihydrate form. J Urol 2008;179:1615-1619.
69. Jung T, Kim WS, Choi CK: Biomineralization of calcium oxalate for controlling crystal structure and morphology. Mat Sci Eng C 2004;24:31-33.
70. Tomazic BB, Nancollas GH: A study of the phase transformation of calcium oxalate trihydratemonohydrate. Invest Urol 1979;16:329-335.
71. Fliser D, Wittke S, Mischak H: Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes. Electrophoresis 2005;26:2708-2716.
72. Kolch W, Neususs C, Pelzing M, Mischak H: Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005;24:959-977.
73. Weissinger EM, Hertenstein B, Mischak H, Ganser A: Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis. Expert Rev Proteomics 2005;2:639-647.
74. Liu BC, Zhang L, Lv LL, Wang YL, Liu DG, Zhang XL: Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am J Nephrol 2006;26:483-490.
75. Thongboonkerd V, Songtawee N, Sritippayawan S: Urinary proteome profiling using microfluidic technology on a chip. J Proteome Res 2007;6:2011-2018.